Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation
Alan P Skarbnik(Novant Health), Andrew L. Pecora(Hackensack University Medical Center), Paul Fields(Adaptive Biotechnologies (United States)), Lori A. Leslie(Hackensack University Medical Center), Dante B. Descalzi‐Montoya(Hackensack Meridian Health), Tatyana Feldman(Hackensack University Medical Center), Robert Korngold(Georgetown University), Noa Biran(Hackensack University Medical Center), Pashna N. Munshi(Johns Hopkins Hospital), Scott D. Rowley(Johns Hopkins Hospital), Joshua Zenreich(Hackensack University Medical Center), Rena Feinman(Georgetown University), André Goy(Hackensack University Medical Center), Themba Nyirenda(Hackensack University Medical Center), Michèle L. Donato(The University of Texas Health Science Center at Houston), David H. Vesole(Hackensack University Medical Center)
Cited by 16
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k